DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  

Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

 Key Statistics


Email: hr@oculusis.com
Ownership: Public

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









 Company News
Oculus Innovative Sciences, Inc. (OCLS)' Partner, More Pharma Corporation, Launches Microcyn®-Based Oral And Throat Infection Treatment Product In Mexico 4/22/2014 8:54:54 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Receives "Strong Consensus" Rating For Use With Kinetic Concepts, Inc. (KCI)' Negative Pressure Wound Therapy With Instillation 4/9/2014 8:00:55 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Shakes Up Board Following Ruthigen IPO 4/2/2014 9:23:36 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Announces Appointment Of Sharon Barbari To Its Board Of Directors 3/27/2014 9:53:31 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) To Raise $1.35 Million In Registered Direct Offering 2/24/2014 8:59:25 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Receives Approval For Oral And Throat Infection Products In Mexico 2/19/2014 8:44:22 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $3.3 Million For Third Quarter Of Fiscal 2014 2/14/2014 9:14:27 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Announces Completion Of Agreements Required For IPO By Company's Subsidiary, Ruthigen 2/7/2014 9:18:57 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Receives European CE Mark For Use Of Microcyn® In The Topical Treatment Of Mild To Moderate Acne 2/4/2014 7:14:24 AM    More...
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Third Quarter 2014 Financial Results And Conference Call 1/30/2014 9:02:04 AM    More...
12345678910...